Alanylglutamine

Drug Profile

Alanylglutamine

Alternative Names: (D-Glu)-isomer-alanylglutamine; Ala-Gln; Alanyl-glutamine; Dipeptiven; N(2)-L-alanyl-L-glutamine; PD-Protec

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Zytoprotec
  • Class Cytoprotectives; Dipeptides
  • Mechanism of Action Immunosuppressants; Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Peritonitis

Most Recent Events

  • 10 Nov 2016 Zytoprotec completes a phase II trial for Peritonitis (prevention, in patients with chronic renal failure) in Austria (EudraCT2013-000400-42)
  • 21 Jul 2016 Alanylglutamine is still in phase II trials for Peritonitis (prevention, in patients with chronic renal failure) in Austria (EudraCT2013-000400-42)
  • 13 May 2014 Phase-II clinical trials in Peritonitis (prevention, in patients with chronic renal failure) in Austria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top